Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(12):950; doi:10.1093/jnci/93.12.950
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Harris, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harris, J. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 12, 950, June 20, 2001
© 2001 Oxford University Press

CORRESPONDENCE

Re: Comparison of Three Management Strategies for Patients With Atypical Squamous Cells of Undetermined Significance: Baseline Results From a Randomized Trial

Jeffrey E. Harris

Correspondence to: Jeffrey E. Harris, M.D., Ph.D., Department of Economics, Massachusetts Institute of Technology, E52–252F, Cambridge, MA 02139 (e-mail: JEFFREY@MIT.EDU).

In their study of alternative management strategies for women with equivocal Pap smears, Solomon et al. (1) concluded that "HC 2 [Hybrid Capture 2TM] testing for cancer-associated HPV [human papillomavirus] DNA . . . has greater sensitivity to detect CIN3 [cervical intraepithelial neoplasia grade 3] or above and . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?